Customer Attitudes Around Prescription Drug Pricing and the Role of Pharmacy Benefit Managers
The costs for prescription drugs keep rising, which puts pressures on the wallets of Americans, and more importantly has a potentially devastating...
Why Reform in Our Industry Is Needed Now More Than Ever
In the wake of the class action brought against Johnson & Johnson (J&J), alleging breach of fiduciary duties, the pharmacy benefit management (PBM)...
Navitus to Remove Humira® from Formularies Effective June 1
More than ten biosimilars to Humira® were launched in 2023, introducing price competitiveness for one of the most utilized drugs on the market....
Humira Biosimilars – Update for October Formularies
Our recent August Pharmacy and Therapeutics (P&T) Committee meeting reviewed the release of various Humira® biosimilars. Staying true to our...
Legal Ease: A Navitus Government Affairs Update
In an ever-changing legislative landscape, we want to help our clients and partners stay informed of the latest happenings and how proposed policies...
Humira Biosimilars – Summer of Blockbuster Releases for Navitus to Review
This summer has seen a continuation of the long-awaited market entry of Humira® (adalimumab) biosimilars. As of July 1, nine additional biosimilars...
Transforming Access to Pharmacy Benefits: 2022 Drug Trend Report
We are pleased to share our 2022 Drug Trend Report with you. This year's report highlights our success in managing pharmacy benefit costs for our...
Humira Biosimilars Enter the Marketplace – Update on Navitus’ Review
The market entry of biosimilars to Humira® (adalimumab) is long-awaited. These products have the potential to improve affordability in the near- and...
Five Forecasts and Takeaways for Plan Sponsors in 2023
As we enter 2023, David Fields is sharing his top forecasts and takeaways for plan sponsors and the PBM industry.
Understanding the Inflation Reduction Act of 2022
Navitus’ Vice President of Government Relations, Robyn Crosson, shares her insight into the Inflation Reduction Act and how it will impact our...
Key Findings: 2021 Navitus Drug Trend Report
This week we provide an overview of our 2021 drug trend and client savings with insights for 2022 and beyond.
What You Need to Know About Fraud, Waste and Abuse in The Age of COVID-19
Carrie Aiken, Navitus’ Vice President of Corporate Compliance and Chief Compliance Officer, shares her perspective on how PBMs can help plan sponsors...
